论文部分内容阅读
目的分析和肽素预测急性失代偿性心力衰竭患者近期不良事件的价值。方法选取急性失代偿性心力衰竭患者138例,按照类型分为终点事件组与非终点事件组。对两组患者的N末端B型利钠肽原、和肽素水平对患者的疾病判断和预后评估情况进行分析。结果两组患者的基本指标之间不存在显著差异,P>0.05。纽约心功能Ⅳ患者的N末端B型利钠肽原、和肽素水平明显高于纽约心功能Ⅲ患者,存在显著性差异,P<0.05。N末端B型利钠肽原、和肽素的ROC曲线下面积相比较不存在显著性差异,P>0.05。结论和肽素水平在急性失代偿性心力衰竭疾病的危险分层和判断方面同样具有参考价值,对急性失代偿性心力衰竭患者的预后评估具有直接的影响。
Objective To analyze the value of copeptin in predicting recent adverse events in patients with acute decompensated heart failure. Methods A total of 138 patients with acute decompensated heart failure were selected and divided into end-point event group and non-end-point event group according to their types. The two groups of patients with N-terminal B-type natriuretic peptide and copeptin levels in patients with disease judgment and prognosis assessment were analyzed. Results There was no significant difference between the two groups in the basic indicators, P> 0.05. N-terminal B-type natriuretic peptide and copeptin levels in NYHA IV patients were significantly higher than those in NYHA III patients (P <0.05). There was no significant difference in the area under the ROC curve between N-terminal B-type natriuretic peptide and copeptin, P> 0.05. Conclusions Copeptin levels are equally valuable in the risk stratification and judgment of acute decompensated heart failure and have a direct impact on the prognosis of patients with acute decompensated heart failure.